Literature DB >> 32249179

Evaluation of the urethral α/β ratio and tissue repair half-time for iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.

Toshio Gocho1, Masakazu Hori1, Yuuki Fukushima1, Masanori Someya1, Mio Kitagawa1, Tomokazu Hasegawa1, Takaaki Tsuchiya1, Masato Hareyama2, Masaru Takagi2, Kohei Hashimoto3, Naoya Masumori3, Koh-Ichi Sakata4.   

Abstract

PURPOSE: To assess the correlation between postimplant dosimetric quantifiers and the genitourinary (GU) toxicity of low-dose rate brachytherapy for prostate cancer. METHODS AND MATERIALS: The minimum urethral dose (UD10, 30, and 90) and the percent volume of the urethra receiving the prescription dose (V100, V150) were calculated from the postimplant dose-volume histograms of 182 patients. We then calculated various urethral biologically equivalent doses (uBEDs) using different values of the α/β ratio and tissue repair half-time (t1/2) and examined the correlations with GU toxicity.
RESULTS: Common dosimetric quantifiers, such as UD90 (brachytherapy) + UD50 (external beam radiotherapy), showed no correlation with Grade ≥ 2 GU toxicity. There was a significant correlation between Grade ≥2 GU toxicity and uBED when the α/β value was 0.5 or 1 Gy and t1/2 was 0.5-2.5 h. An uBED (α/β = 1.0, t1/2 = 0.5) had the largest hazard ratio for GU toxicity, and it was also significantly correlated with Grade ≥ 2 GU toxicity according to multivariate analysis.
CONCLUSIONS: We observed a significant correlation of uBED with GU toxicity when α/β was 0.5 or 1.0 Gy and t1/2 was 0.5-2.5 h. As the simple formula we used has not been verified in basic experiments, more data are needed to validate our results.
Copyright © 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biologically equivalent dose; Late genitourinary toxicity; Low-dose-rate brachytherapy; Prostate cancer; Tissue repair half-time; α/β ratio

Mesh:

Substances:

Year:  2020        PMID: 32249179     DOI: 10.1016/j.brachy.2020.02.007

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  1 in total

1.  A Novel Framework for the Optimization of Simultaneous ThermoBrachyTherapy.

Authors:  Ioannis Androulakis; Rob M C Mestrom; Miranda E M C Christianen; Inger-Karine K Kolkman-Deurloo; Gerard C van Rhoon
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.